BBIO - Bridgebio Pharma Inc Stock Price, Fair Value and News

25.46USD+0.39 (+1.56%)Market Closed

Market Summary

USD25.46+0.39

Market Closed

1.56%

BBIO Stock Price

View Fullscreen

BBIO RSI Chart

BBIO Valuation

Market Cap

4.5B

Price/Earnings (Trailing)

-6.85

Price/Sales (Trailing)

60.35

Price/Free Cashflow

-8.46

BBIO Price/Sales (Trailing)

BBIO Profitability

Operating Margin

97.73%

Return on Equity

48.64%

Return on Assets

-119.56%

Free Cashflow Yield

-11.82%

BBIO Fundamentals

BBIO Revenue

BBIO Earnings

Earnings (TTM)

-653.3M

Earnings Growth (Yr)

-21.17%

Earnings Growth (Qtr)

5.1%

Breaking Down BBIO Revenue

Last 7 days

0.9%

Last 30 days

-13.9%

Last 90 days

-29.7%

Trailing 12 Months

67.4%

How does BBIO drawdown profile look like?

BBIO Financial Health

Current Ratio

3.32

Debt/Equity

-0.33

Debt/Cashflow

-1.18

BBIO Investor Care

Shares Dilution (1Y)

16.16%

Diluted EPS (TTM)

-3.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	79.3M	88.8M	98.4M	107.9M
2021	23.6M	39.0M	54.3M	69.7M
2020	0	0	24.4M	8.2M
2019	0	0	0	40.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Bridgebio Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	scott randal w.	sold	-85,000	34.00	-2,500	-
Feb 16, 2024	homcy charles j	sold (taxes)	-56,149	37.21	-1,509	-
Feb 16, 2024	homcy charles j	acquired	-	-	3,760	-
Feb 16, 2024	kumar neil	sold (taxes)	-1,783,180	37.21	-47,922	ceo and president
Feb 16, 2024	stephenson brian c	acquired	-	-	44,996	secretary, treasurer & cfo
Feb 16, 2024	stephenson brian c	sold (taxes)	-703,976	37.21	-18,919	secretary, treasurer & cfo
Feb 16, 2024	kumar neil	acquired	-	-	102,249	ceo and president
Feb 15, 2024	valantine hannah	sold	-110,041	37.75	-2,915	-
Feb 15, 2024	valantine hannah	acquired	24,631	8.45	2,915	-
Jan 16, 2024	valantine hannah	sold	-110,683	37.97	-2,915	-

Which funds bought or sold BBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Stonegate Investment Group, LLC	unchanged	-	-1,610	12,856	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	845,460	2,437,940	0.02%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	reduced	-2.82	-93,655	272,622	-%
Apr 19, 2024	Handelsinvest Investeringsforvaltning	reduced	-34.18	-149,000	151,000	0.07%
Apr 19, 2024	CALDWELL SUTTER CAPITAL, INC.	reduced	-31.25	-61,160	68,024	0.03%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	9.2	-27,624	141,243	-%
Apr 18, 2024	Diversified Trust Co	added	57.08	144,580	856,545	0.03%
Apr 18, 2024	SJS Investment Consulting Inc.	added	11.76	-99.00	588	-%
Apr 17, 2024	Fox Hill Wealth Management	added	4.23	-6,506	79,403	0.05%
Apr 17, 2024	First Bank & Trust	new	-	248,318	248,318	0.05%

Are Funds Buying or Selling BBIO?

Are funds buying BBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BBIO

No. of Funds

Unveiling Bridgebio Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	kumar neil	5.59%	9,959,504	SC 13G/A
Feb 13, 2024	vanguard group inc	7.36%	12,800,294	SC 13G/A
Jan 29, 2024	blackrock inc.	5.8%	10,156,773	SC 13G/A
Jan 23, 2024	state street corp	2.92%	5,086,899	SC 13G/A
Nov 22, 2023	viking global investors lp	15.7%	25,120,991	SC 13D/A
Jul 20, 2023	viking global investors lp	15.7%	25,120,991	SC 13D/A
Feb 14, 2023	kumar neil	6.42%	9,823,908	SC 13G/A
Feb 09, 2023	vanguard group inc	7.09%	10,591,455	SC 13G/A
Feb 08, 2023	state street corp	5.92%	8,844,943	SC 13G
Feb 01, 2023	blackrock inc.	6.6%	9,834,401	SC 13G/A

Recent SEC filings of Bridgebio Pharma Inc

View All Filings

Date Filed	Form Type	Document
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 06, 2024	424B5	Prospectus Filed
Mar 06, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading
Mar 04, 2024	424B5	Prospectus Filed
Mar 04, 2024	8-K	Current Report
Feb 22, 2024	10-K	Annual Report
Feb 22, 2024	8-K	Current Report
Feb 21, 2024	4	Insider Trading

Peers (Alternatives to Bridgebio Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Bridgebio Pharma Inc News

Latest updates

Bridgebio Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4	2019Q3
Revenue	-	-	-	-	-	108	60.00	13.00	2.00	54.00	27.00	0.00	8.00	17.00	27.00
Cost Of Revenue	-	1.00	-	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-
Costs and Expenses	40.0%	179	128	131	129	154	175	179	152	148	168	128	128	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	168	128	128	92.00	81.00
S&GA Expenses	53.0%	48.00	31.00	32.00	31.00	36.00	44.00	55.00	46.00	46.00	45.00	37.00	36.00	35.00	23.00
R&D Expenses	40.2%	130	93.00	91.00	93.00	108	108	122	104	102	123	90.00	92.00	57.00	55.00
EBITDA Margin	-	-	-	-	-	-	-	7.97*	10.11*	14.03*	23.26*	65.90*	7.19*	7.35*	1.66*
Interest Expenses	0.7%	20.00	20.00	20.00	20.00	20.00	20.00	15.00	11.00	11.00	10.00	11.00	11.00	3.00	2.00
EBT Margin	-	-	-	-	-	-	-	7.25*	9.30*	12.97*	21.40*	61.28*	6.57*	7.12*	1.58*
Net Income	-19.3%	-170	-142	-140	-140	-2.56	-201	-152	-161	-102	-171	-135	-130	-84.15	-60.66
Net Income Margin	-46.3%	-5.78*	-3.95*	-4.49*	-5.04*	-5.82*	-7.78*	-8.41*	-10.47*	-13.81*	-24.24*	-	-	-	-
Free Cashflow	13.2%	-125	-144	-94.04	-135	-32.85	-161	-136	-128	-94.00	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-16.6%	546	655	504	626	623	729	862	813	1,013	782	1,081	1,093	704	788	905	990	632	641	326	465
Current Assets	-18.7%	478	588	433	553	549	642	771	716	889	640	910	945	643	745	862	925	569	558	307	445
Cash Equivalents	-25.6%	376	505	302	407	377	483	470	372	394	180	378	471	356	367	541	757	364	414	294	436
Net PPE	-4.8%	12.00	12.00	13.00	14.00	15.00	16.00	17.00	17.00	30.00	28.00	26.00	23.00	20.00	16.00	16.00	16.00	6.00	3.00	2.00	2.00
Liabilities	2.2%	1,889	1,849	1,853	1,839	1,868	1,859	1,877	1,854	1,878	1,517	1,537	1,481	596	569	578	538	156	116	114	88.00
Current Liabilities	35.6%	144	106	110	97.00	121	119	141	103	135	96.00	132	95.00	96.00	76.00	93.00	65.00	60.00	40.00	39.00	33.00
Long Term Debt	1.1%	446	442	440	436	431	-	-	434	431	103	103	91.00	92.00	93.00	93.00	92.00	92.00	75.00	75.00	55.00
LT Debt, Non Current	1.1%	446	442	440	436	431	-	-	434	431	103	103	91.00	92.00	93.00	93.00	92.00	92.00	75.00	75.00	55.00
Shareholder's Equity	-Infinity%	-1,343	-	-	-	-1,243	-	-	-	-867	-	-	-	106	216	326	449	474	522	211	377
Retained Earnings	-7.0%	-2,560	-2,392	-2,215	-2,057	-1,918	-1,780	-1,643	-1,633	-1,436	-1,289	-1,133	-1,037	-888	-768	-652	-531	-440	-366	-306	-179
Additional Paid-In Capital	1.5%	1,481	1,460	1,128	1,107	939	917	893	868	842	821	800	767	1,021	1,007	993	987	848	826	469	494
Shares Outstanding	0.5%	175	174	161	160	151	148	146	146	144	147	143	-	-	-	-	-	-	-	-	-
Minority Interest	-9.4%	11.00	12.00	12.00	12.00	11.00	10.00	12.00	-0.03	3.00	5.00	7.00	6.00	48.00	52.00	60.00	68.00	65.00	62.00	48.00	62.00
Float	-	-	-	2,075	-	-	-	977	-	-	-	5,000	-	-	-	0.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	14.1%	-124,819	-145,226	-113,353	-144,322	-93,243	-135,163	-30,453	-160,635	-133,895	-121,561	-91,713	-150,765	-96,261	-131,684	-87,849	-83,920	-76,203	-49,996	-68,248	-59,140	-46,414
Share Based Compensation	63.8%	37,025	22,600	27,178	21,907	21,789	17,361	28,287	24,122	19,774	16,042	30,112	33,577	12,146	17,699	18,392	10,222	10,007	5,777	3,358	2,232	3,113
Cashflow From Investing	-100.2%	-66.00	37,682	4,119	12,298	17,965	146,857	149,702	138,623	21,800	58,968	458	-282,052	83,018	-45,050	-128,984	38,023	-16,901	-197,342	-583	-2,427	-3,599
Cashflow From Financing	-101.5%	-4,523	307,040	-1,231	150,249	6,377	1,445	-20,796	-160	325,381	-135,456	-1,391	547,912	4,531	2,782	703	439,173	42,904	367,508	-9,969	-1,651	274,174
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	997	-
Buy Backs	-	-	-	-	-	-	-	-	-	1,542	143,150	5,308	50,000	-	-	-	75,000	-	-	-	-	-

BBIO Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 9,303	$ 77,648	$ 69,716
Operating costs and expenses:
Cost of revenue	2,446	3,434	3,114
Research and development	455,711	399,462	451,024
Selling, general and administrative	150,590	143,189	192,210
Restructuring, impairment and related charges	7,926	43,765	0
Total operating costs and expenses	616,673	589,850	646,348
Loss from operations	(607,370)	(512,202)	(576,632)
Other income (expense), net:
Interest income	18,038	7,542	1,133
Interest expense	(81,289)	(80,438)	(46,778)
Gain from sale of priority review voucher, net	0	107,946	0
Other income (expense), net	17,370	(7,500)	35,823
Total other income (expense), net	(45,881)	27,550	(9,822)
Net loss	(653,251)	(484,652)	(586,454)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests	10,049	3,469	23,915
Net loss attributable to common stockholders of BridgeBio	$ (643,202)	$ (481,183)	$ (562,539)
Net loss per share attributable to common stockholders of BridgeBio, basic	$ (3.95)	$ (3.26)	$ (3.9)
Net loss per share attributable to common stockholders of BridgeBio, diluted	$ (3.95)	$ (3.26)	$ (3.9)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic	162,791,511	147,473,076	144,356,619
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted	162,791,511	147,473,076	144,356,619

BBIO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 375,935	$ 376,689
Marketable securities	0	51,580
Investment in equity securities	58,949	43,653
Receivable from licensing and collaboration agreements	1,751	17,079
Restricted cash	16,653	37,930
Prepaid expenses and other current assets	24,305	21,922
Total current assets	477,593	548,853
Property and equipment, net	11,816	14,569
Operating lease right-of-use assets	8,027	10,678
Intangible assets, net	26,319	28,712
Other assets	22,625	20,224
Total assets	546,380	623,036
Current liabilities:
Accounts payable	10,655	11,558
Accrued compensation and benefits	57,370	31,256
Accrued research and development liabilities	29,765	39,803
Operating lease liabilities, current portion	4,128	3,675
Deferred revenue, current portion	6,096	8,156
Accrued professional and other accrued liabilities	35,830	26,980
Total current liabilities	143,844	121,428
Term loan, net	446,445	430,993
Operating lease liabilities, net of current portion	8,981	12,274
Other long-term liabilities	9,361	26,643
Total liabilities	1,888,915	1,867,960
Commitments and contingencies (Note 9)
Redeemable convertible noncontrolling interests	478	(1,589)
Stockholders' deficit:
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 181,274,712 shares issued and 175,082,951 shares outstanding as of December 31, 2023, 156,817,333 shares issued and 150,625,572 shares outstanding as of December 31, 2022	181	157
Treasury stock, at cost; 6,191,761 shares as of December 31, 2023 and December 31, 2022	(275,000)	(275,000)
Additional paid-in capital	1,481,032	938,703
Accumulated other comprehensive income (loss)	31	(328)
Accumulated deficit	(2,560,501)	(1,918,149)
Total BridgeBio stockholders' deficit	(1,354,257)	(1,254,617)
Noncontrolling interests	11,244	11,282
Total stockholders' deficit	(1,343,013)	(1,243,335)
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit	546,380	623,036
2029 Notes
Current liabilities:
Notes, net	736,905	734,988
2027 Notes
Current liabilities:
Notes, net	$ 543,379	$ 541,634

About Bridgebio Pharma Inc

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

CEO	Dr. Neil Kumar Ph.D.
WEBSITE	bridgebio.com
INDUSTRY	Biotechnology
EMPLOYEES	392

Bridgebio Pharma Inc Frequently Asked Questions

What is the ticker symbol for Bridgebio Pharma Inc? What does BBIO stand for in stocks?

BBIO is the stock ticker symbol of Bridgebio Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bridgebio Pharma Inc (BBIO)?

As of Tue Apr 23 2024, market cap of Bridgebio Pharma Inc is 4.48 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BBIO stock?

You can check BBIO's fair value in chart for subscribers.

What is the fair value of BBIO stock?

You can check BBIO's fair value in chart for subscribers. The fair value of Bridgebio Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bridgebio Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bridgebio Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether BBIO is over valued or under valued. Whether Bridgebio Pharma Inc is cheap or expensive depends on the assumptions which impact Bridgebio Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BBIO.

What is Bridgebio Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, BBIO's PE ratio (Price to Earnings) is -6.85 and Price to Sales (PS) ratio is 60.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BBIO PE ratio will change depending on the future growth rate expectations of investors.